Rakovina Therapeutics Inc Cash Flow Conversion Efficiency
Rakovina Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Rakovina Therapeutics Inc (RKV) has a cash flow conversion efficiency ratio of -0.548x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-1.04 Million ≈ $-748.85K USD) by net assets (CA$1.89 Million ≈ $1.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Rakovina Therapeutics Inc (2021–2024)
Cash flow conversion efficiency of Rakovina Therapeutics Inc from 2021 to 2024. This chart illustrates how Rakovina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Rakovina Therapeutics Inc (RKV) share price today for real-time trading data and today's change.
Rakovina Therapeutics Inc Cash Flow Conversion Ratio Explained
Rakovina Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Rakovina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rakovina Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Rakovina Therapeutics Inc (RKV) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Calidi Biotherapeutics Inc.
NYSE MKT:CLDI
|
-1.342x |
|
Omega Therapeutics Inc
NASDAQ:OMGA
|
-1.214x |
|
Smooth Rock Ventures Corp
V:SMRV
|
-0.028x |
|
NORTHERN SHIELD RES INC.
F:N9SA
|
N/A |
|
Sylvania Platinum Limited
LSE:SLP
|
0.095x |
|
Empire Metals Limited
LSE:EEE
|
-0.098x |
|
Lithium Universe Ltd
AU:LU7
|
0.447x |
|
FEEDBACK PLC LS-5
F:GZM0
|
N/A |
Annual Cash Flow Conversion Efficiency for Rakovina Therapeutics Inc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Rakovina Therapeutics Inc from 2021 to 2024. Review Rakovina Therapeutics Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$4.30 Million ≈ $3.11 Million |
CA$-3.86 Million ≈ $-2.79 Million |
-0.897x | -76.29% |
| 2023-12-31 | CA$3.66 Million ≈ $2.65 Million |
CA$-1.86 Million ≈ $-1.35 Million |
-0.509x | -59.59% |
| 2022-12-31 | CA$6.01 Million ≈ $4.35 Million |
CA$-1.92 Million ≈ $-1.39 Million |
-0.319x | -17.99% |
| 2021-12-31 | CA$8.54 Million ≈ $6.18 Million |
CA$-2.31 Million ≈ $-1.67 Million |
-0.270x | -- |
About Rakovina Therapeutics Inc
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series … Read more